Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-29 | Bruce Wendel (3) 2021 184,086 1,122,658 1,306,744 |
| 2022-08-17 | Bruce Wendel |
| 2023-05-01 | Bruce Wendel, Vice Chairman of the Board |
| 2023-11-06 | Bruce Wendel (5) Includes shares underlying options to purchase 558,333 shares of common stock. |
| 2024-04-29 | Mr. Wendel was appointed to our Board of Directors on November 11, 2020. From April 2018 to May 2019, Mr. Wendel served as the Chief Business Development Officer for Prometic Biotherapeutics, Inc., a pharmaceutical development company. |
| Filing Date | Source Excerpt |
|---|---|
| 2017-04-10 | "Mr. Wendel earned a juris doctorate degree from Georgetown University Law School, and a B.S. from Cornell University." |
| 2018-04-10 | "Prior to Abraxis, Mr. Wendel served in business and corporate development roles of increasing responsibility... Mr. Wendel earned a juris doctorate degree from Georgetown University Law School, and a B.S. from Cornell University." |
| 2018-11-19 | "Bruce Wendel" |
| 2019-04-08 | Prior to this, Mr. Wendel served in business and corporate development roles of increasing responsibility at American Pharmaceutical Partners, IVAX Corporation and Bristol-Myers Squibb. |
| 2020-04-08 | "Mr. Wendel... served in business and corporate development roles... Mr. Wendel earned a juris doctorate degree from Georgetown University Law School, and a B.S. from Cornell University." |
| 2021-04-08 | "Prior to Abraxis, Mr. Wendel served in business and corporate development roles... Mr. Wendel earned a juris doctorate degree from Georgetown University Law School, and a B.S. from Cornell University." |
| 2022-04-01 | "Bruce Wendel (4)" |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-07-26